Triptorelin PBS listing restores certainty for Australian women

Triptorelin PBS listing restores certainty for Australian women Eddy Midgley Sat, 26/09/2026 - 22:03 Over the past few months, I heard from women living with breast cancer who were scared about what the future held for their treatment. These women relied on a medicine called Zoladex as part of their care. For many, it was a medicine they had used for years. Then, suddenly, they were facing the prospect that it would no longer be available in Australia on the Pharmaceutical Benefits Scheme (PBS). The uncertainty around the potential removal of 3.6mg dose of Zoladex by pharmaceutical company AstraZeneca from the Australian market understandably caused enormous concern. Women wanted to know what it meant for them. Would there be another treatment available? Would it work for them? Would they be able to afford it? And, importantly, would they be able to continue their care without disruption? For some women with breast cancer, ovarian suppression is a critical part of their treatment. It can help reduce the risk of cancer returning or help control metastatic breast cancer. For younger women undergoing chemotherapy, it can also help preserve the possibility of having children in the fut

Résiliable à tout moment · 99 $ CA/mois